| Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase studied in …STUDIED_INderived28 of 28show fewer |
|---|
| → studied in | NCT07469891Phase 1 · recruiting A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03862157Phase 1/Phase 2 · active not recruiting Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04717414Phase 3 · active not recruiting An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03441113Phase 2 · active not recruiting Extended Access of Momelotinib in Adults With Myelofibrosis · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04517851Phase 2 · active not recruiting Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06351631Phase 3 · recruiting A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787487Phase 2 · completed Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07362225recruiting MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551066Phase 3 · terminated To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551053Phase 3 · terminated To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785870not yet recruiting EVAluation of Erythrocytosis PRospEctive Cohort STudy · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755518Phase 3 · terminated A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218628Phase 1 · recruiting Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02124746Phase 2 · completed Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04896112Phase 1 · withdrawn A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02098161Phase 2 · completed LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05882773recruiting Asian Myeloproliferative Neoplasm (MPN) Registry · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03895112Phase 1 · completed MPN-RC 118 AVID200 in Myelofibrosis · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01423851Phase 1/Phase 2 · completed Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02055781Phase 3 · terminated Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04283526Phase 1 · withdrawn Study of Select Combinations in Adults With Myelofibrosis · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01773187Phase 3 · terminated Pacritinib Versus Best Available Therapy to Treat Myelofibrosis · condition mapped ALIAS · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00397813Phase 2 · completed Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02871323Phase 1 · withdrawn Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04054245Phase 2 · withdrawn PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02421354Phase 2 · terminated Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01298934Phase 1/Phase 2 · unknown LBH589 (Panobinostat) for the Treatment of Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01291784Phase 1 · terminated Anti-TGF-beta Therapy in Patients With Myelofibrosis · condition mapped ONTOLOGY_EXACT · 28 trials mapped (10 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 1 | Observed | clinicaltrials | graph → |